OnKure Therapeutics, Inc. Class A Common Stock (OKUR) Stock Price
OKURStock
$3.85+37.46%52W
Market Cap$155.91M
P/E—
PEG Ratio—
Div yield—
Beta0.10
OKUR Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)45.61%
Price vs S&P 500 (4W)-4.57%
VGM Score62.31
OKUR Earnings Surprise History
Q2 25-1.14est. -1.25
Q3 25-1.09est. -1.20
Q4 25-0.99est. -1.15
Q1 26-1.11est. -0.74
Q2 26-0.31est. -0.54
OKUR Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.25
4.17
4.17
4.17
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
OKUROnKure Therapeutics, Inc. Class A Common Stock | — | — | B | $3.85 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About OnKure Therapeutics, Inc. Class A Common Stock
OnKure Therapeutics is a clinical-stage biopharmaceutical company developing precision cancer medicines that target biologically validated disease drivers in underserved indications. The company focuses on oncology areas with limited existing treatment options.